ZD 9379 manufacturers
- ZD-9379
-
- $912.00
-
2026-04-20
- CAS:170142-20-8
- Purity:
- Supply Ability: 10g
|
| | ZD 9379 Basic information |
| Product Name: | ZD 9379 | | Synonyms: | ZD 9379;7-CHLORO-2,3-DIHYDRO-2-(4-METHOXY-2-METHYLPHENYL)PYRIDAZINO [4,5-B] QUINOLINE-1,4,10(5H)TRIONE;Pyridazino[4,5-b]quinoline-1,4,10(5H)-trione, 7-chloro-2,3-dihydro-2-(4-methoxy-2-methylphenyl)- | | CAS: | 170142-20-8 | | MF: | C19H14ClN3O4 | | MW: | 383.79 | | EINECS: | | | Product Categories: | | | Mol File: | 170142-20-8.mol |  |
| | ZD 9379 Chemical Properties |
| density | 1.54±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | <19.19mg/ml in DMSO; <7.68mg/ml in 1eq. NaOH | | pka | 9.25±0.20(Predicted) |
| | ZD 9379 Usage And Synthesis |
| Uses | 7-Chloro-2,3-dihydro-2-(4-methoxy-2-methylphenyl)pyridazino[4,5-b]quinoline-1,4,10(5H)-trione is a N-methyl-D-aspartate receptor antagonist and a neuroprotective agent. | | in vivo | ZD-9379 (5 mg/kg) reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion[1]. | Animal Model: | Male Sprague-Dawley rats weighing 290 to 340 g undergoing permanent middle cerebral artery occlusion (MCAO)[1] | | Dosage: | 5 mg/kg | | Administration: | Group1: a 5-mg/kg bolus of ZD-9379 over 5 minutes followed by 5 mg/kg per hour drug infusion for 4 hours beginning 30 minutes before MCAO.
Group 2: (post-MCAO treatment group), a 5-mg/kg bolus of ZD-9379 30 minutes after MCAO followed by 5 mg/kg per hour drug infusion for 4 hours. | | Result: | Initiated before or after MCAO significantly reduced the number of Spreading depressions (SDs) and infarct volume in a permanent focal ischemia model.
|
|
| | ZD 9379 Preparation Products And Raw materials |
|